PUBLISHER: IMARC | PRODUCT CODE: 1675300
PUBLISHER: IMARC | PRODUCT CODE: 1675300
The global reproductive genetics market size reached USD 7.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 59.8 Billion by 2033, exhibiting a growth rate (CAGR) of 25.13% during 2025-2033. The growing awareness and understanding of genetic disorders among the masses, the rising adoption of preventive healthcare, and the increasing fertility rates leading to a higher uptake of assisted reproductive technologies (ART) represent some of the key factors driving the market.
Reproductive genetics refers to the branch of genetics that focuses on the study of genetic information and its impact on reproductive health and outcomes. It involves the analysis and understanding of genetic factors related to fertility, pregnancy, and the transmission of genetic disorders from parents to their offspring. Reproductive genetics encompasses various techniques and technologies aimed at identifying and managing genetic conditions during the reproductive process. Screening individuals or couples for specific genetic mutations or carrier status to assess the risk of passing on genetic disorders to their children. In assisted reproductive technologies such as in vitro fertilization (IVF), PGD involves the analysis of embryos for genetic abnormalities before their implantation in the uterus, helping to select embryos without specific genetic disorders. Reproductive genetics helps assess the risk of transmitting genetic disorders to offspring by identifying carrier status or the presence of specific genetic mutations in individuals or couples.
The global market is primarily driven by the growing awareness and understanding of genetic disorders among the masses. Also, the rising adoption of preventive healthcare leading to a higher number of prospective parents undergoing genetic testing to understand the risks of genetic disorders in their future children is fueling the market. With the increasing fertility rates, there is a higher uptake of assisted reproductive technologies (ART) such as In-Vitro Fertilization (IVF) and surrogacy, which is creating a positive market outlook. In line with this, continual technological developments in advanced genetic testing techniques such as Next-Generation Sequencing (NGS) and high-resolution microarrays are stimulating the market. Moreover, the increasing maternal age resulting in a higher susceptibility of chromosomal abnormalities in women is providing an impetus to the market. In addition to this, governments of several countries are increasingly supporting genetic research and testing, thereby catalyzing the growth of the market. The market is further driven by the rising affordability of genomic sequencing procedures, resulting in higher accessibility among the masses. Some of the other factors contributing to the market include inflating income levels, particularly in developing countries, the proliferation of organizations offering direct-to-consumer genetic tests, continual innovations in personalized medicine, and extensive research and development (R&D) activities.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.